Association for Research in Vision and Ophthalmology

Strong correlation between fish intake and reduced severity of the disease.

The condition disproportionately affects minorities and the poor.

The esteemed ophthalmologist was candid, thoughtful in deep interview with MD.

Incremental ratio was too high even with most favorable scenario for aflibercept.

Nguyen has had the fortune of having been involved in the trials of all three.

Nguyen speaks of the implications sirolimus could have if approved by the FDA.

Researcher speaks on his team's findings regarding uveitis candidate sirolimus.

Eye conditions help explain uptick in collisions.

"I’ve been going to ARVO for 20 years...every year I learn a lot,” Loewenstein says.

$100,000 award for up to 3 winners in a race to grow the best artifical retinas.

The biggest unmet need nowadays in retina disease is geographic atrophy..."

It does show that there is a difference between the drugs,” she says.

$1 million is up for grabs

Babies exposed to marijuana in the womb may require clinical care sooner.

Patients in tocilizumab treatment group 4 times more likely to see remission.

With many manifestations, giant cell arteritis must be addressed across specialties.

Retinal cell replacement counters effects of glaucoma in lab settings.

Algorithm able to correctly predict drusen progression with encouraging accuracy.

Ophthalmology has made great strides in recent years treating many of the more commonly seen conditions, but work is being done to address some of the more rare problems, as well.

Even a decade ago the technology used in diagnosis for ophthalmology was still developing. In that time work has been done to improve the ways doctors can see the potential problems their patients may have to provide a higher level of care.

A condition like chronic traumatic encephalopathy is only able to be diagnosed now after a patient has already died. New technology is being developed to help patients while they are still alive. These new techniques could also be used to help other conditions as well.

For more than a decade medical researchers have been learning more about their fields from studying the injuries sustained by soldiers on the battlefield. A recent study looked at vision loss in this patient population, particularly in regards to traumatic brain injury.

While cataracts may be one of the most common conditions being treated the National Eye Institute is also looking at ways to treat other less commonly seen issues as well.

Cataracts are one of the most common diagnosis in eye care but there is still work being done to help treat the condition in the most effective way possible.

Yutao Liu, MD, PhD, Georgia Regents University, discussed how he and his team can potentially target genes to either reduce glaucoma or provide neuroprotection specifically for the mitochondria in the retina.

A patch that uses patients’ own stem cells to protect them from vision loss will soon begin phase 1 trials.

Results from the ATLAS study show that patients with wet AMD treated with Eylea experienced visual and anatomic improvements after 1 year that were sustained after 2 years.

Phase 2a trial of novel topical anti-angiogenic agent regorafenib shows lack of efficacy in neovascular age-related macular degeneration.

According to Henry Kaplan, MD, University of Louisville School of Medicine, "One has to recognize that there are multiple approaches like gene therapy, neuroprotection, stem cell transplantation, and pharmacologic manipulation of other genes really holds the greatest benefit in terms of trying to reverse the inevitable loss of vision."

Henry Kaplan, MD, KY Lions Eye Center, University of Louisville School of Medicine, is focusing his efforts on figuring out how to preserve or recover lost central vision in patients with retinitis pigmentosa.